Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Move Over, Vial. In a new titra/news/conference-coverage/donanemab-small-tweak-titration-big-gain-safetytion protocol (bottom ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...

Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new “disease modifying” treatments for Alzheimer’s disease ...

The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...

Donanemab was evaluated in a main study (Phase III Study TRAILBLAZER-ALZ 2) involving 1,736 patients with early Alzheimer’s disease who had mild cognitive impairment, mild dementia and evidence ...

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.

Donanemab, also known as Kisunla, has recently been licensed as a treatment for early-stage Alzheimer’s disease in the UK. However, donanemab has not been recommended for use in the NHS. Here's what ...